When adverse effects occur within the same exposure range required for efficacy and cannot be mitigated through dosing, formulation, or pathway bias, biological failure is likely
GLP-1 receptor agonists, a class of medication used to treat type 2 diabetes and obesity, are sold under many brand names, including Wegovy, Ozempic, and Mounjaro
Hypoglycemia events were rare, with the incidence ranging from 0.2% to 1.7% in the tirzepatide groups and 0.4% in the semaglutide group.In conclusion, tirzepatide demonstrated superior glycemic control and weight loss compared to semaglutide in patients with type 2 diabetes
How Wegovy works Wegovy contains semaglutide, a GLP-1 receptor agonist
The very low rates of hypoglycemia are an additional advantage in vulnerable patients, such as the elderly or patients who live alone
Medical circumstances vary between individuals always seek advice from a qualified healthcare professional before making decisions about health, treatment, or participation in clinical research
